1. Introduction {#s0005}
===============

Hepatic encephalopathy (HE) has a harmful impact on chronic and acute liver illnesses and affects more than one third of patients with liver cirrhosis. After overt episodes, the one-year mortality of these patients varies from 42 to 64%, which is even worse than the values attributed to other complications ([@bb0055]; [@bb0110]; [@bb0215]). Hyperammonemia is the chief disturbance in HE physiopathology, when the conversion of ammonia to glutamine (GLN) is fully activated in extrahepatic tissues, thus increasing the influx of intracellular water into astrocytes due to GLN osmoregulation ([@bb0050]). Furthermore, the high permeability of the blood-brain barrier facilitates the influx of ammonia to the brain under inflammatory conditions ([@bb0010]). For practical purposes, in this article the word ammonia is used to represent ammonia free base (NH3) plus ammonium (NH4+).

HE treatment is based on controlling the trigger factors and managing ammonia production and absorption from the gut, by using disaccharides or antibiotics. Since many patients do not achieve sufficient improvement, branched-chain amino acids (BCAA) and drugs aiming to increase ammonia conversion to urea are often added as adjuvant therapies.

Among all these options, BCAA (leucine, isoleucine and valine) have the least understood mechanism of action. The efficacy of these substances in HE treatment is well established from systematic reviews and meta-analyses ([@bb0085]). Even so, the amount of BCAA and the proportion of each amino acid that patients should receive is still a matter of controversy, because all clinical trials until now used them together, making it impossible to analyze the influence of each one on HE manifestations. Of note, BCAA are not only linked to HE improvement but also to increased cerebral perfusion ([@bb0105]).

The key disturbance in aminoacidemia related to HE is ammonia accumulation, which is present in \>80% of patients according to the diagnostic methods adopted ([@bb0005]). The main ammonia source in cirrhotic patients is the intestinal catabolism of GLN from the blood, in addition to a lesser content produced by intestinal bacteria ([@bb0175]; [@bb0245]). In normal adults, the daily amount produced is approximately 1000 mmol ([@bb0240]). When the conversion of ammonia to urea is insufficient, hyperammonemia increases GLN production in skeletal muscles and the brain ([@bb0135]). Since most patients with cirrhosis present moderate to severe malnutrition and loss of muscle mass, the high levels of circulating ammonia will increase glutamine production in the brain, thereby worsening HE manifestations ([@bb0150]; [@bb0195]).

The chief extrahepatic detoxifying process in mammals is the activity of glutamine synthetase ([@bb0075]), which begins with the conversion of glutamate (GLU) and ammonia into GLN (Eq. [(1)](#fo0005){ref-type="disp-formula"}). This reaction requires GLU provided from BCAA catabolism in skeletal muscles, where BCAA and α-ketoglutarate (α-KG) can be converted to GLU and branched-chain ketoacids (Eq. [(2)](#fo0010){ref-type="disp-formula"}) ([@bb0095]).$$\left. {GLU} + {NH}3 + {ATP}\rightleftarrows{GLN} + {ADP} + {Pi} \right.$$$$\left. \text{BCAA} + \alpha - {KG}\rightleftarrows{GLU} + \text{BCKA} \right.$$

Hyperammonemia decreases extracellular BCAA and increases the release of branched-chain ketoacids from the muscle ([@bb0100]). The reversible nature of these reactions makes the concentrations of substrates and products the main regulators of these processes ([@bb0100]). Consequently, the patients would have high levels of ammonia, GLN and branched-chain ketoacids, but lower levels of BCAA in the extracellular fluid.

BCAA deficiency has a large impact on the tricarboxylic acid (TCA) cycle, because leucine and valine are involved in the generation of Acetyl-CoA and Succinyl-CoA, respectively, whereas isoleucine is the only amino acid that generates both of these products ([Fig. 1](#f0005){ref-type="fig"}). Therefore, the BCAA deficiency can lead to an impaired TCA cycle.Fig. 1Schematic representation of relevant metabolic reactions related to hyperammonemia and branched-chain amino acids. A = Pyruvate dehydrogenase, B = α-ketoglutarate dehydrogenase, C = glutamate dehydrogenase (the predominant reaction is the formation of α-ketoglutarate), D = glutamine synthetase, E = phosphate-activated glutaminase, F = pyruvate carboxylase, (→→→) = multiple steps, (\-\-\-\-\-\--) = mitochondrial membrane. Some of the most important steps related to this study are shown in the gray rectangle.Fig. 1

The effects of BCAA in the context of HE have been extensively studied ([@bb0030]; [@bb0095]; [@bb0130]; [@bb0250]). Nevertheless, there is no standardization as to BCAA doses. In general, leucine, isoleucine and valine are administered together and in different proportions ([@bb0130]; [@bb0145]). As a result, the appropriate amount of each amino acid to be prescribed is still unknown, but leucine and isoleucine are important to the oxidative metabolism of astrocytes ([@bb0030]; [@bb0115]; [@bb0160]; [@bb0165]).

The present study hypothesizes that the long-term effects of isoleucine leads to a higher increase in cerebral perfusion than that obtained by leucine, thus promoting different degrees of recovery from HE according to the amino acid received by the subjects. Hence, the study was focused on brain areas that are known for being more affected by hypoperfusion, such as the basal ganglia ([@bb0045]; [@bb0120]; [@bb0205]), as well as regions where altered perfusion was already reported in HE and/or acquired hepatocerebral degeneration, such as the hippocampus, prefrontal cortex, medial temporal cortex, anterior cingulate cortex and parietooccipital regions ([@bb0140]; [@bb0170]; [@bb0220]; [@bb0225]; [@bb0255]). Perfusion alterations in some of these regions were already associated with HE symptoms in prior studies, while some areas were reported as having dissimilar blood flow responses after BCAA administration ([@bb0065]; [@bb0105]; [@bb0140]; [@bb0170]; [@bb0225]). Therefore, the primary aim of this study was to evaluate the effects of leucine and isoleucine supplementation on cerebral perfusion in patients with persistent HE. Secondary aims were to assess HE grade, body composition measurements and quality of life. The assessments were performed at 1, 8 and 12 months of treatment, and the serum amino acid levels were measured before and after the trial.

2. Materials and methods {#s0010}
========================

Patients aged \>18 years with cirrhosis and persistent HE who attended the Hepatology units at UNESP Hospital (Botucatu, São Paulo state, Brazil) from 2014 to 2015 were invited to participate. Patients with other neurological diseases, hepatocellular carcinoma, prior liver transplantation or acute-on-chronic liver failure were excluded, as well as those who were already taking BCAA or had started/changed medications for HE treatment in the last week before entering the trial. Thus, only patients taking the same medications and doses for at least one week were included. The study was approved by the Comitê de Ética em Pesquisa (protocol number 4334/2012 at 09/03/2012) and received the Brazilian trial registration number RBR-8t4bf3. The study protocol was conducted according to the Declaration of Helsinki and its revisions. All the subjects or their caregivers signed the informed consent. When the patient was not able to sign, the signature of a family member was obtained.

Liver cirrhosis was established from a liver biopsy or from clinical and complementary exams. Clinical and nutritional evaluations were carried out before the supplementation and bimonthly afterwards, including anthropometric evaluation and handgrip strength measures.

HE was graded according to the West Haven criteria proposed by Amodio et al. and endorsed by the American and European Guidelines ([@bb0020]; [@bb0230], [@bb0235]). Grade 0 comprised subjects without clinical signals of HE, in whom minimal HE was diagnosed according to specific exams (electroencephalogram). Grades I and II were categorized according to the current Guidelines ([@bb0230], [@bb0235]), thus classifying each neurological finding into a specific form. Since only outpatients were recruited, those with HE Grades III and IV were not included.

2.1. Sample size calculation and randomization plan {#s0015}
---------------------------------------------------

In a similar study, the brain perfusion standard deviation in the parietal lobe was 14% and increased by 20% after BCAA administration ([@bb0105]). Considering these same values, with respective alpha and beta errors of 0.05 and 0.2, the sample size required to find significant differences between the groups would be 16 subjects.

The subjects were randomized to participate in one of two groups. Additional information is included as Supplementary material. A control group under placebo treatment was not included due to ethical concerns, in agreement with prior recommendations ([@bb0015]; [@bb0200]). The flow diagram of the patients included is shown in [Fig. 2](#f0010){ref-type="fig"}.Fig. 2Flow diagram of the subjects.Fig. 2

Each packet contained 5.0 g of maltodextrin, 1.8 g of maltitol and 1.2 g of flavoring plus 10.0 g of the amino acid, which was [l]{.smallcaps}-leucine or [l]{.smallcaps}-isoleucine according to the subjects\' randomization (Ajinomoto® and Basecol Mix Indústria e Comércio de Alimentos LTDA, Brazil).

After starting the supplementation, the suggested schedule was to take 3 packets daily mixed in 200 mL of juice or dairy drinks ingested during breakfast, lunch and an evening snack for 12 months. BCAA doses of 30 g were previously given daily to HE patients by [@bb0130]. Each subject was reevaluated every other month, when the adherence to treatment and the remaining packets were checked. Monthly phone calls were made to assure that the subjects were taking the supplement according to the trial schedule.

Before the amino-acid supplementation, the subjects were submitted to clinical exams, anthropometric assessment, handgrip strength measures, brain SPECT, dynamic brain scintigraphy, electroencephalogram and lab tests. The clinical exam was focused on grading HE and ascites. Laboratory exams included venous ammonia and the tests needed to calculate both the Model of End Stage Liver Disease score and the Child-Pugh classification.

2.2. Electroencephalogram {#s0020}
-------------------------

Electroencephalogram exams were used to diagnose minimal hepatic encephalopathy. Acquisition information is included as Supplementary Material.

2.3. Single Photon Emission Computed Tomography (SPECT) {#s0025}
-------------------------------------------------------

The subject was kept in a supine position and free from audiovisual stimuli for at least 20 min before performing the brain SPECT acquisitions. Caffeine, alcohol and stimulants were not allowed starting on the day before the exam. Each patient received 1110 MBq (30 mCi) of 99mTc-bicisate ethyl cysteinate dimer through a peripheral vein one hour before the acquisition. A dual-headed gamma camera (Millennium MG system, General Electric, UK) was employed to acquire the images.

The photopeak was centered at 140 keV with 20% energy using low-energy and high-resolution collimators. The acquisition was made in a 128 × 128 matrix with voxel sizes of 2.26 × 2.26 × 2.26 mm^3^, thus resulting in a resolution of 0.44 pixels/mm over 360° rotation performing 65 frames of 25 s each. A fifth-order Butterworth high-pass filter with cutoff frequency of 0.5 cycles/min was applied to perform the filtered backprojection reconstruction ([@bb0155]; [@bb0220]). A specialist who was unaware of the supplement given performed the SPECT analysis (details included as Supplementary material).

2.4. Dynamic brain scintigraphy {#s0030}
-------------------------------

Dynamic brain scintigraphy was also acquired with the patients in a supine position. Immediately before the acquisition, the subjects received 1110 MBq (30 mCi) of 99mTc through a peripheral vein. Images including head, neck and proximal thorax were acquired by a dual-headed gamma camera (Millennium MG system, General Electric, United Kingdom) equipped with low-energy high-resolution photopeak centered at 140 keV and 20% energy. Acquisition information is included as Supplementary material.

2.5. Nutritional assessment and quality-of-life survey {#s0035}
------------------------------------------------------

Nutritional status was evaluated through anthropometric measures and handgrip strength. Quality of life was assessed using the Medical Outcomes Study 36-item Short-Form General Health Survey (SF-36) validated for Portuguese. Additional information is included as Supplementary material.

2.6. Amino-acid dosages {#s0040}
-----------------------

Serum levels of leucine and isoleucine from the subjects before and after the trial were obtained by high-performance liquid chromatography (SCL-10Avp control system, RF-10AXL fluorescence detector, Shimadzu, Japan). Chromatographic separation was achieved in a Shim-pack ISC-07/S1504 Na type sulfone group analysis column (4 mm × 150 mm i.d., 7 μm, Shimadzu, JPN), which was operated at 25 °C. A Shim-pack ISC-30/S0504 ammonia trap column was also used (4 mm × 50 mm i.d.) for suppressing baseline fluctuations that are often experienced in amino acid analysis. Additional information is included as Supplementary material.

2.7. Statistical analysis {#s0045}
-------------------------

Descriptive analysis was presented as median and interquartile ranges. Pretreatment comparisons between the groups were assessed by Mann-Whitney *U* test, whereas the individual results throughout the trial were evaluated by the Wilcoxon U test. The software Sigma Stat 3.5 (Systat Software Inc., San Jose, CA, USA) for Windows was used for the analysis.

Brain perfusion was assessed via the software SPM 12. The paired *t*-test was used to compare acquisitions at 1, 8 and 12 months of treatment with those before the supplementation. The anatomic visualization of the brain perfusion results from all patients of each group was obtained by a *t* statistic image, which was constructed and projected onto a standard high-resolution T1-weighted Magnetic Resonance Image ([@bb0210]). The statistical significance level was defined as *p* \< 0.05 for all the assays. For the SPECT comparisons throughout time, the *p* value was corrected using the false discovery rate (FDR), and some additional analyses were performed with *p* \< 0.001.

3. Results {#s0050}
==========

The subjects\' initial characteristics did not differ between the groups. The number of male/female subjects was 8/3 in the leucine group and 12/4 in the isoleucine group (*p* = 0.152). The mean age was 61 years (52.5--65.7) in the leucine group and 57 years (52.0--62.0) in the isoleucine group (*p* = 0.767). Child-Pugh and MELD scores in the leucine and isoleucine groups were 8.00 (6.00--10.0) and 12.0 (8.50--15.5) in the former and 7.0 (6.5--8.5) and 11.0 (9.5--12.5) in the latter group, respectively (*p* = 0.218 and 0.535). The HE grade was 1 (0--1) in both groups (*p* = 0.909). Seven subjects in the leucine group and nine in the isoleucine group had minimal HE. Four subjects in the leucine group and six in the isoleucine group presented Grade I HE. One subject in the isoleucine group had Grade II HE.

In the SPECT analysis, there were no differences in cerebral perfusion after 1 month of treatment; the results obtained at 8 and 12 months of treatment were not significantly different from the baseline for patients receiving leucine supplements (data not shown). In contrast, a significant increase in cerebral perfusion was registered in the isoleucine group at 8 months of supplementation (*p* \< 0.001) ([Fig. 3](#f0015){ref-type="fig"}A).Fig. 3Voxel-wise paired *t*-test comparison of cerebral perfusion between baseline and 8 months (A) and between baseline and 12 months (B) of isoleucine supplementation. Differences observed by brain SPECT are shown as color-coded regions in a total of 346 mm^3^ for 8 months (hot color scale, threshold *p* \< 0.001 uncorrected) and 48 mm^3^ for 12 months (cold color scale, threshold *p* \< 0.05 uncorrected). In the first row, results are overlaid in an anatomical MRI rendered in the axial orientation from inferior to superior and neurological orientation (right on right). In the second row, the results are overlaid in a tridimensional rendered model of an inflated brain (orientations are described below the renderings in panel B).Fig. 3

The main clusters of increased perfusion at 8 months were localized at: the right temporal lobe/inferior temporal gyrus (516 mm^3^, *p* FDR corrected = 0.028, T value = 6.78, maximal value at x = 63 y = − 40 z = −34 Montreal Neurological Institute coordinates); right cerebral white matter mainly involving the pre-central gyrus region (1356 mm^3^, *p* FDR corrected \<0.0001, T value = 5.46, x = 21 y = −19 z = 50); left cerebral white matter primarily involving the supplementary motor cortex, superior frontal gyrus, pre-central gyrus, middle cingulate gyrus and pre-central gyrus medial segment (8265 mm^3^, *p* FDR corrected \<0.0001, T value = 3.80, x = −18 y = −13 z = 47); deep right cerebral white matter mainly involving the caudate, putamen, thalamus and pallidum (2181 mm3, *p* FDR corrected \<0.0001, T value = 3.52, x = 21 y = −4 z = 14).

This significant effect of isoleucine was also documented at 12 months of treatment. The difference at this time was less prominent when compared to the previous results, as displayed in [Fig. 3](#f0015){ref-type="fig"}B (*p* = 0.05). The main clusters of increased perfusion were localized at: the left cerebral white matter primarily involving the caudate and anterior cingulate gyrus (1119 mm^3^, *p* uncorrected = 0.006, T value = 2.49, maximal value at x = −18 y = 20 z = 20), right cerebral white matter (1983 mm^3^, *p* uncorrected = 0.007, T value = 2.78, x = 21 y = 35 z = 2) and left cerebral posterior white matter mainly involving the thalamus, middle and posterior cingulate gyrus (744 mm^3^, *p* uncorrected = 0.009, T value = 2.35, x = −21 y = −40 z = 17).

To analyze the brain scintigraphy, the slope of the ascending curves of carotids and brain hemispheres were measured in order to quantify the cerebral blood flow. Again, the results obtained at the first month did not differ from those before the trial, and the results obtained at 8 and 12 months of treatment were not significantly different from the baseline for patients receiving leucine supplements (data not shown). In contrast, a clear enhancement of cerebral blood flow at 8 months of supplementation was observed in the isoleucine group, which was shown by the increase of slope curves of both hemispheres. However, it did not reach the significance level at the 12th month ([Table 1](#t0005){ref-type="table"}).Table 1Dynamic brain scintigraphy analyses comparing the slope of the ascending curves obtained from carotids and brain hemispheres. The comparisons were performed between pretreatment values and the results at 8 and 12 months of supplementation.Table 1Amino acidLeucine group (n = 11)Isoleucine group (n = 16)Pretreatment8 months12 monthsPretreatment8 months12 monthsCAR72.8 (67.5--73.4)76.6 (61.1--79.2)69.4 (57.4--73.5)72.0 (62.9--77.0)75.5 (71.2--81.5)71.9 (60.2--79.6)L71.2 (58.7--78.8)72.8 (58.5--75.9)63.7 (59.9--73.5)66.5 (54.6--75.2)70.8 (57.7--77.9)71.5 (55.9--80.1)BHR59.9 (41.1--65.3)60.9 (46.5--63.8)52.8 (39.8--57.7)50.2 (38.8--61.6)62.8 (48.7--75.4)[⁎](#tf0005){ref-type="table-fn"}56.4 (30.8--65.3)L60.6 (39.8--64.1)56.1 (47.2--63.4)55.9 (35.2--61.6)49.2 (30.8--56.7)59.8 (44.9--73.8)[\#](#tf0010){ref-type="table-fn"}52.0 (40.7--66.2)[^1][^2][^3]

The clinical evaluation findings at 8 and 12 months are described in [Table 2](#t0010){ref-type="table"}. There were no significant changes in the Model of End Stage Liver Disease score during the trial. Reductions in Child-Pugh classification and HE grade did not achieve the significance level in the leucine group. In contrast, both Child-Pugh classification points and HE grade decreased at 8 and 12 months in the isoleucine group. Of note, ammonia levels did not change significantly during the trial.Table 2Clinical evaluation findings and laboratory tests comparing pretreatment values with the results at 8 and 12 months of supplementation.Table 2VariablesAmino acidLeucine group (n = 11)Isoleucine group (n = 16)Pretreatment8 months12 monthsPretreatment8 months12 monthsMELD12.0 (8.50--15.5)11.0 (8.00--12.8)12.0 (8.00--12.8)11.0 (9.50--12.5)11.5 (9.50--13.0)12.0 (10.5--13.5)Child-Pugh8.00 (6.00--10.0)7.00 (5.25--7.75)7.00 (6.25--7.75)7.00 (6.50--8.50)6.00 (5.00--6.50)[⁎](#tf0015){ref-type="table-fn"}6.00 (5.00--7.50)HE grade1.00 (0.00--1.00)0.00 (0.00--1.00)0.00 (0.00--0.00)[§](#tf0020){ref-type="table-fn"}1.00 (0.00--1.00)0.00 (0.00--0.00)[§§](#tf0025){ref-type="table-fn"}0.00 (0.00--0.00)[§§§](#tf0030){ref-type="table-fn"}Ammonia (μmol/L)52.0 (27.8--78.2)66.5 (44.0--94.0)77.0 (46.5--114)58.0 (26.5--95.5)55.0 (13.8--94.5)34.0 (20.8--66.0)[^4][^5][^6][^7][^8]

Body assessment measures are shown in [Table 3](#t0015){ref-type="table"}. For most nutritional variables, there were no significant differences between pretreatment values and those measured at the 8th and 12th months, whereas triceps skinfold and handgrip strength increased significantly in both groups. Quality of life survey results are displayed in the Supplementary Material.Table 3Body assessment measures comparing pretreatment values with the results at 8 and 12 months of supplementation.Table 3VariablesAmino acidLeucine group (n = 11)Isoleucine group (n = 16)Pretreatment8 months12 monthsPretreatment8 months12 monthsWeight (kg)82.2 (69.6--90.0)92.4 (78.8--95.4)91.6 (80.4--99.8)69.7 (59.8--77.7)78.0 (69.4--87.3)75.6 (69.8--86.7)BMI (kg/m^2^)30.1 (25.1--34.5)31.5 (29.1--36.9)31.6 (30.3--36.8)26.0 (24.9--28.6)29.7 (26.9--32.3)29.4 (27.4--31.3)AC (cm)30.0 (26.8--34.5)34.0 (30.2--36.5)32.5 (29.5--35.8)30.2 (26.6--32.2)31.0 (28.4--33.9)31.8 (27.0--32.9)TSF (mm)17.0 (10.0--19.8)25.0 (22.0--32.5)[⁎](#tf0035){ref-type="table-fn"}27.0 (20.8--33.6)[⁎](#tf0035){ref-type="table-fn"}16.5 (8.50--21.0)22.0 (17.0--30.0)[⁎](#tf0035){ref-type="table-fn"}23.5 (15.0--28.5)[⁎](#tf0035){ref-type="table-fn"}MAMC (cm)25.7 (22.0--27.9)24.2 (22.2--27.4)23.9 (22.7--25.4)25.5 (23.9--27.0)23.7 (21.5--25.8)23.9 (22.4--25.0)CAMA (cm^2^)42.5 (30.4--53.5)39.9 (29.2--49.6)36.4 (31.2--41.9)41.9 (35.3--48.3)34.7 (26.8--43.2)35.4 (29.8--40.6)APMT (mm)6.00 (4.50--9.00)8.00 (6.50--9.00)9.00 (7.00--10.0)5.50 (4.75--7.25)7.00 (5.00--9.00)7.00 (6.00--8.00)HGS (kg)18.0 (16.5--22.0)28.0 (22.0--38.8)[§](#tf0040){ref-type="table-fn"}28.0 (20.5--41.5)[§§](#tf0045){ref-type="table-fn"}25.5 (18.0--28.5)33.0 (26.5--40.0)[§§§](#tf0050){ref-type="table-fn"}32.0 (26.5--41.0)[§§](#tf0045){ref-type="table-fn"}[^9][^10][^11][^12][^13]

Serum level analysis from subjects under leucine supplementation demonstrated that leucine levels increased from 34.2 nmol/L (23.1--45.5) to 63.0 nmol/L (30.2--120) at 12 months of treatment (*p* = 0.049). In contrast, isoleucine levels changed from 21.2 nmol/L (13.8--22.4) to 21.7 nmol/L (10.9--89.3) in this group (non-significant difference). At this same time, patients under isoleucine supplementation were evidencing a marked increase of both serum amino acids: levels of leucine increased from 27.9 nmol/L (19.9--37.0) to 40.1 nmol/L (27.2--58.9) (*p* = 0.030) while those of isoleucine increased from 14.4 nmol/L (11.3--20.7) to 88.5 nmol/L (20.8--207) (*p* = 0.003).

4. Discussion {#s0055}
=============

The results of this trial suggest that hyperammonemia has a large impact on cerebral energy metabolism, in agreement with previous studies presented by [@bb0040]; [@bb0080]; [@bb0125]; [@bb0180]. Furthermore, in the sample evaluated, isoleucine was able to reduce HE manifestations. The data demonstrate an increase of serum leucine levels at 12 months of supplementation in both groups, accompanied by gains in body assessment measures such as triceps skinfold after 8 and 12 months of supplementation.

Ammonia detoxification inside astrocytes causes an important influx of water to these glial cells due to GLN accumulation and the osmotic effect of this amino acid ([@bb0070]). Concurrently, ammonia metabolism in muscle cells seems to be linked to strength loss, which is proportional to HE severity ([@bb0025]; [@bb0150]). Thus, the results of strength restoration, triceps skinfold augmentation and HE grading improvement during isoleucine supplementation are inexplicable without considering a significant effect of BCAA on energy metabolism, thus decreasing cytotoxic brain edema and restoring muscle strength.

Taken together, these findings on muscular and astrocytic metabolism suggest that ammonia toxicity is related to a disruption in the cellular mechanisms involved in energy metabolism, especially in the brain. Glutamate dehydrogenase (GDH) activity depends on the amount of α-KG and energy from NAD/NADP provided by the TCA cycle, whereas glutamine synthetase activity requires ATP. However, excessive ammonia inhibits the α-ketoglutarate dehydrogenase complex (αKGDH) in this cycle ([@bb0180]), shifting α-KG to GLN production and decreasing the α-KG oxidation to SuccinylCoA and CO~2~, thus contributing to curbing aerobic energy production ([@bb0125]) (Eq. [(3)](#fo0015){ref-type="disp-formula"}).$$\begin{array}{l}
\left. \alpha - {KG}^{2 -} + \text{CoASH}^{4 -} + {NAD}^{-} + H_{2}O\rightleftarrows \right. \\
{\text{Succinyl} - {CoA}4^{-} + {CO}_{3}^{2 -} + \text{NADH}^{2 -} + H^{+}} \\
\end{array}$$

Another piece of evidence that energy metabolism is the key to understanding how leucine and isoleucine can decrease HE manifestations is the formation of α-KG, which is produced when isocitrate is oxidized to α-KG and CO~2~ (Eqs. [(4)](#fo0020){ref-type="disp-formula"}, [(5)](#fo0025){ref-type="disp-formula"}), a step that requires the bonding of a manganese ion to the carbonyl group before the decarboxylation. Thus, αKGDH inhibition by hyperammonemia leads not only to GLN accumulation but also to an interruption in the TCA cycle at α-KG formation ([Fig. 1](#f0005){ref-type="fig"}). Therefore, in advanced liver disease, both the high ammonia levels and the lack of BCAA may act together to impair α-KG production from oxalosuccinate (Eq. [(5)](#fo0025){ref-type="disp-formula"}). In tissues that depend on aerobic processes to obtain energy, such as brain cells, the reduced α-KG formation supposedly decreases the manganese uptake in this process. Consequently, the remaining manganese may accumulate in regions such as basal nuclei and cortical areas, a common finding in patients with HE and acquired hepatocerebral degeneration.$$\left. \text{Isocitrate} + {NAD}/\text{NADP}\rightleftarrows\text{Oxalosuccinate}\  \right.$$$$\text{Oxalosuccinate}\ \overset{{Mn}^{+ 2}}{\rightleftarrows}\ \alpha - {KG} + {CO}_{2}$$

As shown in [Fig. 1](#f0005){ref-type="fig"}, αKGDH inhibition is an additional cause of oxidative metabolism impairment in organs that depend on aerobic processes to obtain energy, such as the brain ([@bb0030]; [@bb0080]; [@bb0125]), thus impairing ATP generation from the TCA cycle. Despite the fact that GLN accumulation in astrocytes causes cytotoxic edema due to the osmotic effect of GLN ([@bb0050]; [@bb0190]), it may be insufficient to account for the astrocytic swelling or the manganese deposits in HE, which only could be explained by additional disturbances, such as metabolic impairment and oxidative stress.

Even though brain perfusion control is not fully understood, there are important reports showing that cerebral blood flow (CBF) is regulated by astrocytes according to brain metabolism by controlling vasoconstriction and vasodilation ([@bb0035]; [@bb0060]). The GLU release by neurons raises intracellular Ca^+2^ in astrocytes, which activates the production of arachidonic acid and vasodilators such as prostaglandins and epoxyeicosatrienoic acids. On the other hand, arachidonic acid can be converted to 20-hydroxyeicosatetraenoic acid in arteriolar smooth muscle, resulting in vasoconstriction. Therefore, the direction toward vasodilation or vasoconstriction in the brain is mediated by metabolic conditions ([@bb0035]; [@bb0060]).

The findings obtained in this trial suggest that astrocytic dysfunction is probably the cause of the cerebral perfusion changes observed in HE. In the SPECT analysis, an augmentation of cerebral perfusion was documented after isoleucine supplementation at 8 and 12 months of treatment as shown in [Fig. 3](#f0015){ref-type="fig"}. The slope of the ascending curves obtained from brain hemispheres, depicting the CBF rise, constituted additional evidence of blood flow improvement at 8 months of isoleucine supplementation ([Table 1](#t0005){ref-type="table"}). Cytotoxic edema recovery seems to constitute a reasonable explanation for the increased perfusion found at 8 and 12 months of treatment in the isoleucine group. However, the CBF improvement observed was greater at 8 months than at 12 months of treatment ([Fig. 3](#f0015){ref-type="fig"}, [Table 1](#t0005){ref-type="table"}).

The imaging technique used in this work was the same employed by [@bb0105], who also reported a CBF improvement in patients with cirrhosis under BCAA supplementation. Nevertheless, given that all BCAA (valine, leucine and isoleucine) were administered together in this previous study, the role of each one in this effect on cerebral perfusion was difficult to distinguish. In this present trial, long-term isoleucine supplementation has led to significant changes in cerebral perfusion, mainly in the white matter. Involvement of the cingulate gyrus and basal ganglia was observed as well. These brain areas were previously reported as being associated with HE symptoms, such as cognitive impairment, lack of attention, memory loss and deficits in visual-spatial perception ([@bb0065]; [@bb0140]; [@bb0170]).

The reason that the results from isoleucine supplementation were better than those obtained from leucine can only be understood by analyzing the effects of ammonia on the TCA cycle. Isoleucine and leucine can both be converted to Acetyl-CoA, but isoleucine is also converted to Succinyl-CoA, providing additional carbon to this cycle at the step when αKGDH is inhibited by ammonia ([@bb0030]; [@bb0090]; [@bb0165]; [@bb0185]). Due to this unique property of isoleucine, it can serve as an ideal substrate for maintaining TCA as a source of energy, even in the presence of hyperammonemia, by reestablishing oxaloacetate to form citrate from Acetyl-CoA ([@bb0115]). Therefore, BCAA supplementation is capable of restoring the oxidative metabolism in neural cells, especially when a larger amount of isoleucine is administered, because it can reduce the disruption in ion transportation through the cell membranes, thus maintaining the osmotic regulation and probably reducing the cytotoxic edema observed in HE.

In addition to its role in TCA cycle maintenance, isoleucine is also involved in ammonia detoxification when α-KGDH is inhibited ([@bb0185]). This additional role of isoleucine might reduce the GLN concentration in astrocytes, thereby avoiding the cytotoxic edema. The evidence supporting this property of isoleucine is that the subjects who received isoleucine presented elevated serum levels of both isoleucine and leucine. On the other hand, leucine supplementation led to an increase only in this same amino-acid serum level, probably due to the fact that leucine supplies Acetyl-CoA only for the TCA cycle, which requires isoleucine to provide Succinyl-CoA and keep the cycle running ([Fig. 1](#f0005){ref-type="fig"}) ([@bb0115]; [@bb0185]).

Both leucine and isoleucine supplementations improved the quality of life related to physical functioning, most likely by restoring energy generation and strength, as shown by the handgrip strength elevation in both groups, indicating that some symptoms were ameliorated. Although the increase in cerebral perfusion was more pronounced at 8 months, the clinical improvement was maintained until the end of the trial and the subjects did not suffer HE deterioration. Therefore, the increase obtained in cerebral perfusion may be a compensatory mechanism induced by isoleucine in the first months, leading to a partial restoration in the metabolic coupling between cerebral regions. The results suggest that this mechanism was activated to a lesser degree when the subjects achieved improvement in their HE manifestations, a hypothesis in line with relevant studies on this issue ([@bb0065]; [@bb0255]). Last but not least, four subjects in the leucine group exited the trial because they had experienced nausea and vomiting. The lack of such terminations in the isoleucine group leads to the suspicion that isoleucine preparations may be more palatable than leucine preparations.

In conclusion, the results of this double-blind randomized clinical trial showed that isoleucine supplementation facilitates the achievement of a better impact on brain perfusion and HE grade than that obtained by leucine, suggesting that patients with cirrhosis and HE should receive supplements enriched with a higher level of isoleucine than leucine.
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[^1]: CA = carotids; BH = brain hemispheres; R = right; L = left. Data are expressed as median (1st quartile--3rd quartile).

[^2]: *p* = 0.05.

[^3]: *p* \< 0.029.

[^4]: MELD = model for end-stage liver disease; Child-Pugh = Child-Pugh classification; HE = hepatic encephalopathy. Data are expressed as median (1st quartile--3rd quartile). The upper normal limit for plasma ammonia levels is 35 μmol/L.

[^5]: *p* \< 0.001.

[^6]: *p* = 0.055.

[^7]: *p* = 0.008.

[^8]: *p* = 0.004.

[^9]: BMI = body mass index; AC = arm circumference; TSF = triceps skinfold; MAMC = mid-arm muscle circumference; CAMA = correct mid-arm muscle area; APMT = adductor pollicis muscle thickness; HGS = handgrip strength; kg = kilogram, kg/m^2^ = kilogram per square meter, cm = centimeter, mm = millimeter. Data are expressed as median (1st quartile--3rd quartile).

[^10]: *p* ≤ 0.001.

[^11]: *p* = 0.010.

[^12]: *p* = 0.002.

[^13]: *p* = 0.001.
